Meeting Report

Collaborative Management of Patients With Estrogen Receptor–Positive Breast Cancer

Presented by Lee S. Schwartzberg, MD, FACP, and Heather R. Greene, MSN, FNP, AOCNP®

West Cancer Center, Memphis, Tennessee

Presenters’ disclosures of potential conflicts of interest are found at the end of this article.


J Adv Pract Oncol 2017;8:250–254 | https://doi.org/10.6004/jadpro.2017.8.3.6 | © 2017 Harborside Press®


  

ABSTRACT

Cyclin-dependent kinase (CDK) inhibitors represent a new form of cytotoxic chemotherapy. Advanced practitioners can read this article to find out about the science behind CDK inhibition, when CDKs are indicated, how to monitor for and manage side effects, as well as when and how to dose adjust.


For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here
click me